Physician profile
Mark L Arey
NPI 1801906664
$6,235.45
in general payments reported to CMS, 2019-2025
23 companies · $608 in 2025
The $608 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,368 · 2020: $290 · 2021: $438 · 2022: $875 · 2023: $1,745 · 2024: $912 · 2025: $608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,265.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,468.37 | 2019-2025 | Clareon, Rocklatan, Acrysof Iq Panoptix Uv Iol |
| Abbvie INC. | $772.83 | 2022-2025 | Durysta |
| Sun Pharmaceutical Industries INC. | $715.32 | 2019-2025 | Cequa |
| Glaukos Corporation | $367.23 | 2023-2025 | Istent Trabecular Micro-Bypass System Model Is3, Idosetr |
| Bausch & Lomb Americas INC. | $343.18 | 2023-2025 | Miebo, Vyzulta |
| New World Medical,INC. | $270.85 | 2023 | |
| Kala Pharmaceuticals, INC. | $268.94 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $255.63 | 2019 | |
| Horizon Therapeutics Plc | $237.64 | 2022-2023 | Tepezza |
| Regeneron Healthcare Solutions, INC. | $235.69 | 2019-2025 | Eylea Hd |
| Allergan, INC. | $228.62 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $190.80 | 2019 | |
| Genentech USA, INC. | $158.09 | 2023 | Vabysmo |
| Dompe US, INC. | $148.00 | 2023-2024 | Oxervate |
| Ivantis, INC | $136.82 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $131.82 | 2020 | |
| Amgen INC. | $71.58 | 2024-2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $66.89 | 2021-2023 | |
| Oyster Point Pharma, INC. | $66.31 | 2022-2024 | Tyrvaya, Ryzumvi |
| Rxsight INC | $38.53 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Tarsus Pharmaceuticals, INC. | $24.93 | 2024 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $19.98 | 2023 | Lipiflow System Activator (Disposable) |
| Shire North American Group INC | $17.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Arey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.